PMID: 11607037Oct 19, 2001Paper

Eplerenone: a selective aldosterone receptor antagonist (SARA)

Cardiovascular Drug Reviews
J A DelyaniB Whelihan

Abstract

Aldosterone, the final product of the renin-angiotensin-aldosterone system (RAAS), is a mineralocorticoid hormone that classically acts, via the mineralocorticoid (aldosterone) receptor, on epithelia of the kidneys, colon, and sweat glands to maintain electrolyte homeostasis. Aldosterone has also been shown to act at nonepithelial sites where it can contribute to cardiovascular disease such as hypertension, stroke, malignant nephrosclerosis, cardiac fibrosis, ventricular hypertrophy, and myocardial necrosis. Although angiotensin-converting enzyme (ACE) inhibitors and angiotensin type 1 (AT(1)) receptor antagonists act to suppress the RAAS, these agents do not adequately control plasma aldosterone levels--a phenomenon termed "aldosterone synthesis escape." Spironolactone, a nonselective aldosterone receptor antagonist, is an effective agent to suppress the actions of aldosterone; its use is, however, associated with progestational and antiandrogenic side effects due to its promiscuous binding to other steroid receptors. For these reasons, eplerenone--the first agent of a new class of drugs known as the selective aldosterone receptor antagonists (SARAs)--is under development. In rodent models, eplerenone provides marked protectio...Continue Reading

References

Dec 8, 1988·The New England Journal of Medicine·G H Williams
Dec 1, 1995·European Heart Journal·J P BonvaletM Lombès
Jan 1, 1997·Hypertension·Y TakedaR Takeda
Feb 1, 1997·Annals of Medicine·K HelinT Unger
Mar 28, 1998·The Journal of Biological Chemistry·J S SilvestreC Delcayre
Jul 9, 1998·Journal of Human Hypertension·M G NichollsM Agarwal
Jul 29, 1998·Environmental Health Perspectives·R N HillD V Singh
Jul 17, 2001·American Journal of Physiology. Heart and Circulatory Physiology·J A DelyaniA E Rudolph

❮ Previous
Next ❯

Citations

Jul 29, 2003·Expert Opinion on Investigational Drugs·Amar M Salam
Jun 24, 2004·Current Treatment Options in Cardiovascular Medicine·Anita Deswal, David Yao
Mar 23, 2007·American Journal of Physiology. Renal Physiology·Rudy M OrtizL Gabriel Navar
Aug 24, 2007·American Journal of Physiology. Renal Physiology·Rudy M OrtizKenneth D Mitchell
Jan 8, 2008·Current Hypertension Reports·Paolo CravediGiuseppe Remuzzi
Apr 22, 2009·Expert Opinion on Drug Metabolism & Toxicology·James A MuldowneyCassandra D Benge
Jul 10, 2010·Journal of Renal Care·David BenaventeCharles J Ferro
Aug 6, 2016·Drug Development and Industrial Pharmacy·Prakash Namdeo Kendre, Pravin Digambar Chaudhari
Dec 30, 2016·Journal of Clinical Pharmacology·Masayo OishiKevin Sweeney
Jun 21, 2019·British Journal of Clinical Pharmacology·Simon B DimmittRobin E Ferner
Jun 27, 2002·Expert Opinion on Pharmacotherapy·Sheila A Doggrell, Lindsay Brown
Jun 14, 2005·Journal of Clinical Pharmacology·William R RavisDwain S Tolbert
Apr 20, 2004·Assay and Drug Development Technologies·Sohail A QureshiSteven A Hayes
May 21, 2004·Expert Review of Cardiovascular Therapy·Henry Krum, Danny Liew
Jul 11, 2006·Der Internist·M Quinkler, M Reincke
Mar 25, 2006·Nephron. Physiology·Ernesto Rodríguez-AyalaRamón Paniagua
Mar 13, 2009·Current Hypertension Reports·Paolo CravediGiuseppe Remuzzi
Apr 14, 2012·The Journal of Veterinary Medical Science·Tsuyoshi HommaMasahiro Ikeda
Apr 30, 2017·Current Hypertension Reports·Radmila Lyubarova, Elvira O Gosmanova
Feb 25, 2006·Endocrinology·Tracy A WilliamsPaolo Mulatero
May 17, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masaki AsaiTakao Saruta
Aug 22, 2003·Cardiovascular Drug Reviews·Charles T Stier
Aug 26, 2006·Pediatric Cardiology·Brady S Moffett, Anthony C Chang
Jul 17, 2015·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jessica A ChadwickJill A Rafael-Fortney
Aug 16, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Iwona DamsMichał Chodyński
Oct 4, 2019·The Journal of Pharmacy and Pharmacology·Kawa Dizaye, Zana A Mustafa
Dec 10, 2003·Expert Opinion on Emerging Drugs·J A Whitworth
Apr 20, 2004·Assay and Drug Development Technologies·Chang BaiLeonard P Freedman
Apr 17, 2008·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Frank KramerThomas Krahn
Aug 18, 2018·American Journal of Physiology. Heart and Circulatory Physiology·Janice M Diaz-OteroAnne M Dorrance
Jan 17, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Robert B FelderAlan Kim Johnson
Sep 24, 2002·The Annals of Pharmacotherapy·Alan J Zillich, Barry L Carter
Jul 23, 2020·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Qianqian LiShaofeng Rong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Cardiology in Review
Charles T StierRicardo Rocha
Hypertension Research : Official Journal of the Japanese Society of Hypertension
Yoshiyu Takeda
Cardiovascular & Hematological Agents in Medicinal Chemistry
Coty W JewellDavid E Dostal
© 2021 Meta ULC. All rights reserved